No s'ha trobat cap coincidència exacta per Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis Results from Greater Than 17,000 Patient-Years of Exposure, però canviant-lo per Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate to Severe Psoriasis Results from Greater Than 17 000 Patient Years of Exposure...
Resultats globals: 1 registres trobats en 0.54 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.